Undisclosed NDA Candidate
Undisclosed
NDA SubmittedActive (Priority Review)
Key Facts
About Otsuka
Otsuka America Pharmaceutical, Inc. is the U.S. pharmaceutical arm of Japan's Otsuka Holdings, operating as a commercial-stage biopharmaceutical company. It has a long-standing legacy in neuroscience with marketed products and is actively expanding its pipeline in nephrology, immunology, and CNS disorders through internal R&D and strategic acquisitions like Transcend Therapeutics. The company is led by a seasoned executive team and leverages the global resources of its parent organization to address significant unmet medical needs.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |